Sales & Marketing News | pharmaphorum

News

Nine mid-sized pharmas have signed up for the Trump administration's Most-Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.

News

Takeda and Protagonist's hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera.

News

Sandoz is set to add up to 10 new biosimilar assets to its portfolio under a new collaboration deal with China’s Shanghai Henlius Biotech.

News

After reporting mixed clinical results in a phase 3 trial, Pfizer and Valneva have filed their Lyme disease vaccine candidate PF-07307405 in the EU.

News

Bristol Myers Squibb's CELMoD pipeline has delivered its first approval, for iberdomide, as part of a combination regimen for multiple myeloma.

News

ADC Therapeutics' chances of upgrading its accelerated approval for DLBCL therapy Zynlonta to a full approval have taken a knock.